Document Detail


Reperfusion therapy for acute myocardial infarction. Which strategy for which patient?
MedLine Citation:
PMID:  9664197     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been developed, which differ in terms of effectiveness, complexity and costs. Reperfusion resources are often restricted by budgetary or logistical circumstances. To arrive at an equitable distribution of treatment options, physicians should therefore consider which treatment to apply in which patient. Two major questions which arise in this respect are discussed here: what is the treatment effect in an individual patients, and what is an equitable resource allocation? Currently, the most relevant treatment options are: streptokinase (1.5MU over 1h), reteplase (2 boluses of 10MU), alteplase (tissue plasminogen activator; t-PA) [100mg over 1.5 hours] and immediate angioplasty. In combination with aspirin, streptokinase leads to an almost 40% mortality reduction at 1 month compared with placebo [from 13.2 to 8.0%; Second International Study of Infarct Survival (ISIS-2) trial]. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-1) study demonstrated a further mortality reduction by early combination therapy of aspirin, intravenous heparin and alteplase vs aspirin, heparin (either intravenous or subcutaneous) plus streptokinase (from 7.3 to 6.3%). The clinical effects of reteplase fall somewhere between those of streptokinase and alteplase. Combined analysis of the angioplasty trials suggests that angioplasty is superior to thrombolysis, especially in patients with a high cerebral bleeding risk. The noticed gradient of efficacy runs parallel to a gradient of costs and complexity: streptokinase is the least costly treatment option while direct angioplasty is the most expensive and complex. Subgroup analyses indicate that there are neither apparent deviations in the relative effect of reperfusion therapy as compared to control treatment, nor in the additional effect of more intensive therapy (alteplase) upon 'standard' therapy (streptokinase). Consequently, the absolute number of deaths avoided by reperfusion therapy appears to be greatest in those groups with a high mortality risk without therapy. There is one major exception: in patients treated early after symptom onset a much greater relative mortality reduction is observed than in those treated later. Owing to the higher mortality risk, the life expectancy of a patient with MI is shorter than that of an 'average' person of the same community and the same age. Since mortality reduction of reperfusion therapy is maintained at long term follow-up, part of this potential loss can be regained. This 're-gain of lost years' is judged to be the ultimate treatment effect in an individual patient. An equitable treatment allocation should be such that patients who will benefit most will receive the most effective therapy, while patients with similar expected benefit will be offered the same mode of therapy. The conclusion is that treatment guidelines or protocols can be very useful in clinical practice, especially if rapid decision making is of vital importance.
Authors:
E Boersma; E W Steyerberg; M J Van der Vlugt; M L Simoons
Related Documents :
18640817 - Percutaneous superficial femoral artery interventions for claudication--does runoff mat...
9257667 - Iliac transluminal angioplasty and distal surgical revascularisation can be performed i...
12891107 - Percutaneous arterial closure in peripheral vascular disease: a prospective randomized ...
8627907 - Iliac artery stenoses after percutaneous transluminal angioplasty: follow-up with duple...
16878827 - Outcomes of meniscal repair: minimum of 2-year follow-up.
17586377 - Phacoviscocanalostomy versus cataract surgery only in patients with coexisting normal-t...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  56     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-09-28     Completed Date:  1998-09-28     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  31-48     Citation Subset:  IM    
Affiliation:
University Hospital Rotterdam-Dijkzigt, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty
Aspirin / therapeutic use
Costs and Cost Analysis
Fibrinolytic Agents / therapeutic use
Humans
Myocardial Infarction / drug therapy,  mortality,  therapy*
Myocardial Reperfusion* / adverse effects,  economics
Risk Assessment
Streptokinase / therapeutic use
Time Factors
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 50-78-2/Aspirin; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current drug treatment options in neonatal hyperbilirubinaemia and the prevention of kernicterus.
Next Document:  A practical guide to prescribing hormone replacement therapy.